Zanfina Ademi Delaney

Associate Professor Zanfina Ademi is a scientist in the field of economic evaluation of health care programmes and translational research, and a passionate teacher with substantial expertise in course development and implementation from undergraduate to postgraduate courses. Her research has direct links to policy and practice, being focused on assessing the implications of new and current health technologies in terms of their outcomes and costs, performance characteristics and implications for society and funding.

Following her PhD and Post-Doctoral Fellowship at Monash and the University of Melbourne, Zanfina worked at the University of Basel, Switzerland as a Senior Scientist from 2014 to 2018. She enjoys an international profile, and has demonstrated her expertise through prominent roles, such as participating in European Network  for Health Technology Assessment (EUnetHTA) projects and in the Swiss Network for Health Technology Assessment (SNHTA), a knowledge-exchange network between Swiss researchers in the field of HTA, in conjunction with the Swiss Federal Office of Public Health. For four years until 2018, she led projects addressing policy-relevant activities in the health economic domain, in cooperation with the Swiss Medical Board. Zanfina returned to School of Public Health and Priventive Medicine in early 2018 as Associate Professor, where she will be working on the assessment and economic evalaution of healthcare services, genomic technologies and precision medicine.

Zanfina has been involved in health technology assessment for more than 10 years, in Australia and the European Union, both including government and industry led projects evaluating numerous healthcare interventions, using state of the art economic evalaution methods. To date, her work has involved not just pharmacotherapy (including precision medicine), but also procedures, behavioural interventions, screening and diagnosis.

Zanfina’s research productivity to date is highlighted by over 60 peer-reviewed journal articles, seven commissioned government reports, one book chapter, and over two million in research funding from government and industry. Zanfina holds an expert role for the Global Burden of Disease studies (2013-2018) and has been an invited expert on topics of cost-effectiveness for the British Journal of clinical Pharmacology, cost-effectiveness and oncology for Schweizer Krebsbulletin, and cost-effectiveness and universal screening for Atherosclerosis. She is an invited Editorial Board member for Biomedicine Hub.